Polymer Factory announces the outcome of the exercise of warrants of series TO 1

On 17 March 2022, the exercise period for Polymer Factory Sweden AB’s (“Polymer Factory” or the “Company”) warrants of series TO 1 ended, which was issued in connection with the Company’s issue of units in April 2021. A total of 1,200 warrants of series TO 1 were exercised. Through the warrants of series TO 1, the Company will receive approximately SEK 11,000 before deduction of transaction related costs.

CEO Elin Mignérus comments

“Polymer Factory has had a great last year and increased our net sales with 85 percent during 2021, compared to 2020. During 2022 we will continue to improve our revenue possibilities by expanding our sources of income and we have strengthened our sales organization to intensify our work with attracting new customers. In terms of future development, Polymer Factory have great confidence in our business development, and our operational goals are running according to plan. The Board and I are continuously evaluating alternatives for raising capital.”

Number of shares and share capital

In total, 1,200 warrants of series TO 1 were exercised during the exercise period. Through the exercise of warrants of series TO 1, the Company will thus receive SEK 11,000 before deduction of transaction related costs. When the new shares from the warrant exercise have been registered with the Swedish Companies Registration Office (Sv. Bolagsverket), the total number of shares will amount to 6,860,398 and the share capital will amount to SEK 686,398. The planned conversion date from interim to common shares is expected to take place on 4 April 2022.

For further information about the warrants of series TO 1, please contact:
Sedermera Corporate Finance
+46 (0) 40 615 14 10
cf@sedermera.se
www.sedermera.se

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.